Digoxin Injection
Product Images NDC 51662-1217

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Digoxin (NDC 51662-1217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

00351662121726 Digoxin Pouch Label

Label for DIGOXIN Injection, USP 0.25 mg/mL (500 mcg/2 mL) in a 2 mL ampule. The label includes the NDC 51662-1217-2, lot number 12345, and expiration date 2025-01-01. It states the manufacturer as HF Acquisition Co LLC, Mukilteo, WA, and indicates the product is for slow intravenous or deep intramuscular use.*

FDA Label Image

00351662121733 Digoxin Rfid Label

A close-up image of a label displaying a GS1 DataMatrix barcode along with human-readable GS1 application identifier codes and values, including a Global Trade Item Number (GTIN), expiration date, serial number, and lot number. The label also states "See manufacturer's package insert" and notes distribution by HF Acquisition Co., LLC in Mukilteo, WA. The right edge of the label includes vertical text stating "RX ONLY."*

FDA Label Image

00351662121733 Digoxin Case Label

DIGOXIN Injection label showing strength of 0.25 mg/mL (500 mcg/2 mL), in 2 mL ampoules, box of 25. Label includes NDC 51662-1217-3, lot number 12345, and expiration date 2025-01-01. Manufactured by HF Acquisition Co LLC, Mukilteo, WA 98275. The label notes use for slow intravenous or deep intramuscular injection, storage temperature, and cautions to see the package insert for dosing information.*

FDA Label Image

Ampule (1000180 0641 1410 31 Digoxin Ampule Label)

Label for Digoxin Injection, USP 500 mcg/2 mL (0.5 mg/2 mL or 250 mcg/mL) in a 2 mL ampul, from HF Acquisition Co LLC, DBA HealthFirst. The label indicates use for slow intravenous or deep intramuscular injection and includes the distributor as West-Ward. It shows the NDC 0641-1410-31 and space for lot and expiration data.*

FDA Label Image

Serialized Label (51662 1217 1 Digoxin Serialized)

Ampule of Digoxin Injection USP 0.25 mg/mL, 2 mL liquid, distributed by HF Acquisition Co LLC. The clear glass ampule has a blue label on its neck with dosage and product name, along with a folded informational insert attached. The label includes the NDC code and indicates prescription use only.*

FDA Label Image

Clinical (Clinical Pharmacology Tabel)

A data table comparing Digoxin formulations by their time to onset and peak effect. It shows Digoxin Tablets with onset of 0.5 to 2 hours and peak effect 2 to 6 hours, and Digoxin Injection/IV with onset of 5 to 30 minutes and peak effect 1 to 4 hours.*

FDA Label Image

Dosage 1 (Dosage And Admin Tabel 1)

A data table showing the total IV loading dose in mcg/kg for Digoxin injection by age group. It specifies the dosing for adults and pediatric patients over 10 years old as 8-12 mcg/kg, with instructions to administer half the total loading dose initially, then one quarter of the dose every 6-8 hours twice.*

FDA Label Image

Dosage 2 (Dosage And Admin Tabel 2)

A data table showing total intravenous maintenance dose of Digoxin for adults and pediatric patients over 10 years old, with dosage given once daily ranging from 2.4 to 3.6 mcg/kg/day.*

FDA Label Image

Dosage 3 (Dosage And Admin Tabel 3)

A data table showing corrected values of creatinine clearance (mL/min) across different lean body weights (40 to 100 kg) and the corresponding number of days before steady state is achieved for Digoxin injection. The table includes values for creatinine clearance ranging from 10 to 100 mL/min with days to steady state decreasing as clearance increases.*

FDA Label Image

Dosage 4 (Dosage And Admin Tabel 4)

A data table comparing absolute bioavailability and equivalent doses in micrograms (mcg) for Digoxin tablets and Digoxin intravenous injection. The tablets show 60-80% bioavailability with doses of 62.5, 125, 250, and 500 mcg; the intravenous injection shows 100% bioavailability with doses of 50, 100, 200, and 400 mcg.*

FDA Label Image

Interactions 1 (Drug Interaction Tabel 1)

A data table titled 'Digoxin concentrations increased greater than 50%' and 'Digoxin concentrations increased less than 50%' showing serum concentration increases, AUC increases, and clinical recommendations for various drugs interacting with digoxin. Drugs listed include Quinidine, Ritonavir, Amiodarone, Propafenone, Quinine, Spironolactone, and Verapamil, with associated values and dosing guidance for managing digoxin levels.*

FDA Label Image

Interactions 2 (Drug Interactions Tabel 2)

A data table listing drugs and substances that affect renal function and interact with digoxin, including categories like antiarrhythmics, parathyroid hormone analog, thyroid supplement, sympathomimetics, neuromuscular blocking agents, supplements, beta-adrenergic blockers, calcium channel blockers, and ivabradine, with details on their associated risks and effects when used with digoxin.*

FDA Label Image

Logo (Logo Patient Cons)

FDA Label Image

Structure (Structure)

Chemical structure diagram of digoxin, showing its steroid nucleus and attached sugar moieties. The structure highlights hydroxyl, methyl, and oxygen-containing functional groups characteristic of digoxin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.